RS52221B - Supstituisane n-fenil-bipirolidum uree i njihova terapeutska upotreba - Google Patents

Supstituisane n-fenil-bipirolidum uree i njihova terapeutska upotreba

Info

Publication number
RS52221B
RS52221B RS20120067A RSP20120067A RS52221B RS 52221 B RS52221 B RS 52221B RS 20120067 A RS20120067 A RS 20120067A RS P20120067 A RSP20120067 A RS P20120067A RS 52221 B RS52221 B RS 52221B
Authority
RS
Serbia
Prior art keywords
methyl
phenyl
bipyrrolidinyl
carboxylic acid
amide
Prior art date
Application number
RS20120067A
Other languages
English (en)
Serbian (sr)
Inventor
Lothar Schwink
William J. Hurst
Zhongli Gao
Werngard Czechtizky
Siegfried Stengelln
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of RS52221B publication Critical patent/RS52221B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
RS20120067A 2007-10-17 2008-10-14 Supstituisane n-fenil-bipirolidum uree i njihova terapeutska upotreba RS52221B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98060607P 2007-10-17 2007-10-17
PCT/US2008/079763 WO2009052068A1 (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof

Publications (1)

Publication Number Publication Date
RS52221B true RS52221B (sr) 2012-10-31

Family

ID=40248052

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120067A RS52221B (sr) 2007-10-17 2008-10-14 Supstituisane n-fenil-bipirolidum uree i njihova terapeutska upotreba

Country Status (24)

Country Link
US (1) US8222290B2 (enExample)
EP (1) EP2215058B1 (enExample)
JP (1) JP5380455B2 (enExample)
KR (1) KR20100082349A (enExample)
CN (1) CN101903341B (enExample)
AT (1) ATE534625T1 (enExample)
AU (1) AU2008312641A1 (enExample)
CA (1) CA2702933C (enExample)
CY (1) CY1112391T1 (enExample)
DK (1) DK2215058T3 (enExample)
ES (1) ES2378011T3 (enExample)
HR (1) HRP20120166T1 (enExample)
IL (1) IL205002A0 (enExample)
MA (1) MA31889B1 (enExample)
MX (1) MX2010003948A (enExample)
MY (1) MY148807A (enExample)
NZ (1) NZ584692A (enExample)
PL (1) PL2215058T3 (enExample)
PT (1) PT2215058E (enExample)
RS (1) RS52221B (enExample)
RU (1) RU2478094C2 (enExample)
SI (1) SI2215058T1 (enExample)
WO (1) WO2009052068A1 (enExample)
ZA (1) ZA201002114B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2212283T3 (pl) 2007-10-17 2012-01-31 Sanofi Sa Podstawione karboksyamidy N-fenylobipirolidyny i ich zastosowanie terapeutyczne
CN101903339B (zh) * 2007-10-17 2012-06-27 赛诺菲-安万特 取代的n-苯基-联吡咯烷羧酰胺及其治疗用途
MX2010004003A (es) 2007-10-17 2010-04-30 Sanofi Aventis N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
KR20090129927A (ko) 2008-06-13 2009-12-17 주식회사 엘지화학 발열체 및 이의 제조방법
US9611171B2 (en) 2008-06-13 2017-04-04 Lg Chem, Ltd. Heating element and manufacturing method thereof
US10412788B2 (en) 2008-06-13 2019-09-10 Lg Chem, Ltd. Heating element and manufacturing method thereof
JP5833105B2 (ja) 2010-05-11 2015-12-16 サノフイ 置換n−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用
JP2013526530A (ja) * 2010-05-11 2013-06-24 サノフイ 置換されたn−フェニルスピロラクタムビピロリジン、その製造及び治療上の使用
WO2011143162A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
TW201206910A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
TW201206939A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
AR081034A1 (es) 2010-05-11 2012-05-30 Sanofi Aventis Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central
JP5766278B2 (ja) 2010-05-11 2015-08-19 サノフイ 置換されたn−アルキルおよびn−アシルテトラヒドロ−イソキノリン誘導体、それらの製造および治療上の使用
PE20140913A1 (es) 2010-11-15 2014-08-22 Abbvie Inc Inhibidores de nampt y rock
HRP20151003T1 (hr) * 2011-02-23 2015-10-23 Suven Life Sciences Limited Novi spojevi kao ligandi receptora histamina h3

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
WO2004037257A1 (en) * 2002-10-23 2004-05-06 Janssen Pharmaceutica, N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5052497B2 (ja) 2005-03-17 2012-10-17 イーライ リリー アンド カンパニー ヒスタミンh3受容体アンタゴニストとしてのピロリジン誘導体
BRPI0608653A2 (pt) * 2005-04-01 2010-11-30 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou um sal do mesmo
ES2370518T3 (es) * 2005-07-01 2011-12-19 Eli Lilly And Company Agentes receptores h3 de histamina, preparación y usos terapéuticos.
US7943605B2 (en) * 2005-10-27 2011-05-17 Ucb Pharma S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
CN101903339B (zh) 2007-10-17 2012-06-27 赛诺菲-安万特 取代的n-苯基-联吡咯烷羧酰胺及其治疗用途
PL2212283T3 (pl) 2007-10-17 2012-01-31 Sanofi Sa Podstawione karboksyamidy N-fenylobipirolidyny i ich zastosowanie terapeutyczne
MX2010004003A (es) 2007-10-17 2010-04-30 Sanofi Aventis N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.

Also Published As

Publication number Publication date
MY148807A (en) 2013-05-31
RU2010119554A (ru) 2011-11-27
HK1146056A1 (en) 2011-05-13
EP2215058A1 (en) 2010-08-11
KR20100082349A (ko) 2010-07-16
AU2008312641A1 (en) 2009-04-23
CA2702933A1 (en) 2009-04-23
RU2478094C2 (ru) 2013-03-27
CN101903341A (zh) 2010-12-01
EP2215058B1 (en) 2011-11-23
ES2378011T3 (es) 2012-04-04
JP5380455B2 (ja) 2014-01-08
DK2215058T3 (da) 2012-03-12
IL205002A0 (en) 2010-11-30
CA2702933C (en) 2012-12-18
ATE534625T1 (de) 2011-12-15
MX2010003948A (es) 2010-04-30
MA31889B1 (fr) 2010-12-01
US8222290B2 (en) 2012-07-17
CN101903341B (zh) 2012-10-03
PT2215058E (pt) 2012-03-06
ZA201002114B (en) 2010-12-29
WO2009052068A1 (en) 2009-04-23
HRP20120166T1 (hr) 2012-03-31
CY1112391T1 (el) 2015-12-09
SI2215058T1 (sl) 2012-03-30
JP2011500697A (ja) 2011-01-06
NZ584692A (en) 2011-12-22
US20100173908A1 (en) 2010-07-08
PL2215058T3 (pl) 2012-04-30

Similar Documents

Publication Publication Date Title
RS52221B (sr) Supstituisane n-fenil-bipirolidum uree i njihova terapeutska upotreba
AU2008312635B2 (en) Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
AU2008312636B2 (en) Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine H3 receptor modulators
EP2569294B1 (en) Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
HK1146056B (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
HK1146053B (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof